***TASK*** the task is to summarize an input biomedical literature in six sentences 
    ***INPUT*** the input is a biomedical literature 
    ***OUTPUT*** the output is the summary of an input biomedical literature in six sentences 
    ***DOCUMENTATION*** 
    ***EXAMPLES*** 
    Input: PURPOSE BAY 43 - 9006 ( sorafenib ) is an inhibitor of Raf kinase , the vascular endothelial growth factor ( VEGF ) receptor-2 , and angiogenesis in tumor xenografts . The current study investigated the incidence , severity , and mechanism of  blood pressure ( BP ) elevation in patients treated with BAY 43 - 9006 .  PATIENTS AND METHODS Twenty patients received BAY 43 - 9006 400 mg orally twice daily . BP and heart rate were measured at baseline and then every 3 weeks for 18 weeks . VEGF , catecholamines , endothelin I , urotensin II , renin , and aldosterone were measured at baseline and after 3 weeks of therapy . We assessed vascular stiffness at baseline , after 3 to 6 weeks of therapy , and again after 9 to 10 months of therapy . RESULTS Fifteen ( 75 % ) of 20 patients experienced an increase of > or = 10 mmHg in systolic BP ( SBP ) , and 12 ( 60 % ) of 20 patients experienced an increase of > or = 20 mmHg in SBP compared with their baseline value , with a mean change of 20.6 mmHg ( P < .0001 ) after 3 weeks of therapy . There were no statistically significant changes in humoral factors , although there was a statistically significant inverse relationship between decreases in catecholamines and increases in SBP , suggesting a secondary response to BP elevation . Measures of vascular stiffness increased significantly during the period of observation . CONCLUSION Treatment with BAY 43 - 9006 is associated with a significant and sustained increase in BP . The lack of significant change in circulating factors suggests that these humoral factors had little role in the increase in BP 
    Output:
    
7 Tholstrup D , de Nully Brown P , Jurl and er J , Hansen M. Feasibility , effi cacy and safety of CHOP-14 in elderly patients with very high-risk diff use large B-cell lymphoma .